Author:
Isohashi Fumiaki,Ogawa Kazuhiko,Oikawa Hirobumi,Onishi Hiroshi,Uchida Nobue,Maebayashi Toshiya,Kanesaka Naoto,Tamamoto Tetsuro,Asakura Hirofumi,Kosugi Takashi,Uno Takashi,Ito Yoshinori,Karasawa Katsuyuki,Takayama Makoto,Manabe Yoshihiko,Yamazaki Hideya,Takemoto Mitsuhiro,Yoshioka Yasuo,Nemoto Kenji,Nishimura Yasumasa
Abstract
Abstract
Background
The patterns of radiotherapy (RT) practice for biliary tract cancer (BTC) in Japan are not clearly established.
Methods
A questionnaire-based national survey of RT used for BTC treatment between 2000 and 2011 was conducted by the Japanese Radiation Oncology Study Group. Detailed information was collected for 555 patients from 31 radiation oncology institutions.
Results
The median age of the patients was 69 years old (range, 33–90) and 81% had a good performance status (0–1). Regarding RT treatment, 78% of the patients were treated with external beam RT (EBRT) alone, 17% received intraluminal brachytherapy, and 5% were treated with intraoperative RT. There was no significant difference in the choice of treatment modality among the BTC subsites. Many patients with EBRT were treated with a total dose of 50 or 50.4 Gy (~40%) and only 13% received a total dose ≥60 Gy, even though most institutions (90%) were using CT-based treatment planning. The treatment field consisted of the primary tumor (bed) only in 75% of the patients. Chemotherapy was used for 260 patients (47%) and was most often administered during RT (64%, 167/260), followed by after RT (63%, 163/260). Gemcitabine was the most frequently used drug for chemotherapy.
Conclusions
This study established the general patterns of RT practice for BTC in Japan. Further surveys and comparisons with results from other countries are needed for development and optimization of RT for patients with BTC in Japan.
Publisher
Springer Science and Business Media LLC
Subject
Radiology Nuclear Medicine and imaging,Oncology
Reference20 articles.
1. Park SW, Park YS, Chung JB, Kang JK, Kim KS, Choi JS, Lee WJ, Kim BR, Song SY: Patterns and relevant factors of tumor recurrence for extrahepatic bile duct carcinoma after radical resection. Hepatogastroentelogy 2004, 51: 1612-1618.
2. Matsuda T, Marugame T, Kamo K, Katanoda K, Ajiki W, Sobue T, Japan Cancer Surveillance Research Group: Cancer incidence and incidence rates in Japan in 2006: based on data from 15 population-based cancer registries in the monitoring of cancer incidence in Japan (MCIJ) project. Jpn J Clin Oncol 2012, 42: 139-147. 10.1093/jjco/hyr184
3. Bonet Beltràn M, Allal AS, Gich I, Solé JM, Carrió I: Is adjuvant radiotherapy needed after curative resection of extrahepatic biliary tract cancers? A systematic review with a meta-analysis of observational studies. Cancer Treat Rev 2012, 38: 111-119. 10.1016/j.ctrv.2011.05.003
4. Shinohara ET, Mitra N, Guo M, Metz JM: Radiotherapy is associated with improved survival in adjuvant and palliative treatment of extrahepatic cholangiocarcinomas. Int J Radiat Oncol Biol Phys 2009, 74: 1191-1198. 10.1016/j.ijrobp.2008.09.017
5. Nishimura Y, Koike R, Ogawa K, Sasamoto R, Murakami Y, Itoh Y, Negoro Y, Itasaka S, Sakayauchi T, Tamamoto T: Clinical practice and outcome of radiotherapy for esophageal cancer between 1999 and 2003: the Japanese radiation oncology study group (JROSG) survey. Int J Clin Oncol 2012, 17: 48-54. 10.1007/s10147-011-0254-y
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献